The covalent inhibitors that have been developed for K-Ras G12C offer great promise for the direct inhibition of this Ras mutant; however, most Ras mutants found in cancer, like the Ral proteins, lack an accessible cysteine that can be exploited for inhibition. The gene discussed is KRAS; the disease is cancer.